Cite
Ikeda H, Watanabe T, Shimizu H, et al. Efficacy of ledipasvir/sofosbuvir with or without ribavirin for 12 weeks in genotype 1b HCV patients previously treated with a nonstructural protein 5A inhibitor-containing regimen. Hepatol Res. 2018;48(10):802-809doi: 10.1111/hepr.13074.
Ikeda, H., Watanabe, T., Shimizu, H., Hiraishi, T., Kaneko, R., Baba, T., Takahashi, H., Matsunaga, K., Matsumoto, N., Yasuda, H., Okuse, C., Iwabuchi, S., Suzuki, M., & Itoh, F. (2018). Efficacy of ledipasvir/sofosbuvir with or without ribavirin for 12 weeks in genotype 1b HCV patients previously treated with a nonstructural protein 5A inhibitor-containing regimen. Hepatology research : the official journal of the Japan Society of Hepatology, 48(10), 802-809. https://doi.org/10.1111/hepr.13074
Ikeda, Hiroki, et al. "Efficacy of ledipasvir/sofosbuvir with or without ribavirin for 12 weeks in genotype 1b HCV patients previously treated with a nonstructural protein 5A inhibitor-containing regimen." Hepatology research : the official journal of the Japan Society of Hepatology vol. 48,10 (2018): 802-809. doi: https://doi.org/10.1111/hepr.13074
Ikeda H, Watanabe T, Shimizu H, Hiraishi T, Kaneko R, Baba T, Takahashi H, Matsunaga K, Matsumoto N, Yasuda H, Okuse C, Iwabuchi S, Suzuki M, Itoh F. Efficacy of ledipasvir/sofosbuvir with or without ribavirin for 12 weeks in genotype 1b HCV patients previously treated with a nonstructural protein 5A inhibitor-containing regimen. Hepatol Res. 2018 Sep;48(10):802-809. doi: 10.1111/hepr.13074. Epub 2018 May 04. PMID: 29504692.
Copy
Download .nbib